CR11737A - MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME - Google Patents

MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME

Info

Publication number
CR11737A
CR11737A CR11737A CR11737A CR11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A CR 11737 A CR11737 A CR 11737A
Authority
CR
Costa Rica
Prior art keywords
factor
modified
polypeptides
polipeptides
same
Prior art date
Application number
CR11737A
Other languages
Spanish (es)
Inventor
Alan Brooks
John E Murphy
Marian Seto
Xiaoqiao Jian
Chandra Patel
Uwe Gritzan
Kornelia Kirchner
Ulrich Haupts
Original Assignee
Bayer Schering Pharma Ag
Bayer Healthcare Llc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Bayer Healthcare Llc, Schering Corp filed Critical Bayer Schering Pharma Ag
Publication of CR11737A publication Critical patent/CR11737A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan polipéptidos modificados del factor IX, tales como los polipéptidos del factor IX con uno o más sitios de glicosilación introducidos. Los polipéptidos modificados del factor IX pueden exhibir un incremento de la estabilidad in vitro o in vivo, tal como una semivida plasmática más prolongada. Asimismo se divulgan procedimientos de fabricar polipéptidos modificados del factor IX y a procedimientos de usar modificados del factor IX para, por ejemplo, tratar a pacientes afectados por hemofilia B.Modified factor IX polypeptides, such as factor IX polypeptides with one or more glycosylation sites introduced are disclosed. Modified factor IX polypeptides may exhibit increased stability in vitro or in vivo, such as a longer plasma half-life. Methods of manufacturing modified factor IX polypeptides and methods of using modified factor IX are also disclosed to, for example, treat patients affected by hemophilia B.

CR11737A 2008-04-16 2010-10-15 MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME CR11737A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US4596108P 2008-04-17 2008-04-17

Publications (1)

Publication Number Publication Date
CR11737A true CR11737A (en) 2011-02-07

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11737A CR11737A (en) 2008-04-16 2010-10-15 MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME

Country Status (17)

Country Link
EP (1) EP2288622A4 (en)
JP (1) JP2011517951A (en)
KR (1) KR20110005862A (en)
CN (1) CN102083856A (en)
AU (1) AU2009244633A1 (en)
BR (1) BRPI0910702A2 (en)
CA (1) CA2721683A1 (en)
CO (1) CO6311000A2 (en)
CR (1) CR11737A (en)
DO (1) DOP2010000311A (en)
EC (1) ECSP10010551A (en)
IL (1) IL208718A0 (en)
MX (1) MX2010011345A (en)
RU (1) RU2010146387A (en)
SG (1) SG189790A1 (en)
SV (1) SV2010003704A (en)
WO (1) WO2009137254A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149406A2 (en) * 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
EP2209487A4 (en) * 2007-10-15 2012-06-20 Univ North Carolina HUMAN FACTOR IX VARIANTS WITH EXTENDED HALF-LIFE
FI3581650T3 (en) * 2008-09-15 2023-03-23 Uniqure Biopharma B V Polypeptide mutant of Factor IX, its uses and method for its preparation
PT3552619T (en) 2010-07-09 2025-10-23 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
TWI595004B (en) * 2010-11-03 2017-08-11 介控生化科技公司 Modified ninth factor multi-peptide and use thereof
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
JP5967631B2 (en) * 2012-04-27 2016-08-10 学校法人日本大学 Treatment for epithelial and endothelial damage
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
TWI810729B (en) 2012-09-25 2023-08-01 美商百歐維拉提夫治療公司 Methods of using fix polypeptides
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
FI3889173T3 (en) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimized factor viii gene
TWI828269B (en) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 Factor ix polypeptide formulations
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EP3082848B1 (en) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
JP2017500017A (en) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
SG11201607642RA (en) 2014-03-24 2016-10-28 Biogen Ma Inc Lyophilized factor ix formulations
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods for their preparation and use
KR20180118659A (en) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. Optimized Factor VIII Factor
CN105695616A (en) * 2016-04-22 2016-06-22 王冬国 Analysis marker for diagnosing thyroid cancer and application thereof
MX2019006444A (en) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc HEMOPHILIC ARTHROPATHY TREATMENT METHODS USING CHEMERIC COAGULATION FACTORS.
WO2018144623A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
FR3069540B1 (en) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 MODIFIED PROTEIN WITH IMPROVED HALF-LIFE
BR112020002394A2 (en) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. nucleic acid molecules and uses thereof
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
CN111372612A (en) 2017-09-27 2020-07-03 西吉隆医疗股份有限公司 Methods, compositions and implantable elements comprising viable cells
WO2019195055A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
SI3793588T1 (en) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
KR102925832B1 (en) 2018-08-09 2026-02-11 바이오버라티브 테라퓨틱스 인크. Nucleic acid molecules and their use in non-viral gene therapy
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
US20220323519A1 (en) 2019-04-17 2022-10-13 Codiak Biosciences, Inc. Compositions of exosomes and aav
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
KR20230074703A (en) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. Method for removing free factor VIII from preparations of lentiviral vectors modified to express the protein
WO2022182869A1 (en) 2021-02-24 2022-09-01 Bluehalo Llc System and method for a digitally beamformed phased array feed
US20260102435A1 (en) 2022-10-11 2026-04-16 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
CN120035657A (en) 2022-10-11 2025-05-23 西吉隆医疗股份有限公司 Engineered cells and implantable devices for treating disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (en) * 1988-11-09 1991-04-12 Transgene Sa DNA SEQUENCE ENCODING HUMAN FACTOR IX OR AN ANALOGUE PROTEIN, EXPRESSION VECTOR, TRANSFORMED CELLS, PROCESS FOR PREPARING FACTOR IX, AND PRODUCTS OBTAINED THEREFROM
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
JP2005501547A (en) * 2001-09-04 2005-01-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Modified factor IX
WO2004091487A2 (en) * 2003-04-09 2004-10-28 Wyeth Hemophilia treatment by inhalation of coagulation factors
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2007149406A2 (en) * 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
SG189790A1 (en) 2013-05-31
MX2010011345A (en) 2011-02-23
AU2009244633A1 (en) 2009-11-12
JP2011517951A (en) 2011-06-23
DOP2010000311A (en) 2011-02-28
EP2288622A4 (en) 2012-04-18
CO6311000A2 (en) 2011-08-22
ECSP10010551A (en) 2010-11-30
WO2009137254A3 (en) 2010-01-14
EP2288622A2 (en) 2011-03-02
CA2721683A1 (en) 2009-11-12
WO2009137254A2 (en) 2009-11-12
BRPI0910702A2 (en) 2016-07-05
SV2010003704A (en) 2011-02-21
CN102083856A (en) 2011-06-01
IL208718A0 (en) 2010-12-30
KR20110005862A (en) 2011-01-19
RU2010146387A (en) 2012-05-27

Similar Documents

Publication Publication Date Title
DOP2010000311A (en) MODIFIED POLIPEPTIDES OF FACTOR IX AND USES OF THE SAME
CR20120052A (en) MODIFIED FACTOR IX POLIPEPTIDES AND USES OF THE SAME
DOP2016000042A (en) ANTIBODIES AGAINST THE TYPE 1 (PAI-1) PLASMINOGEN ACTIVATOR INHIBITOR AND USES OF THE SAME
CO6331368A2 (en) MODIFIED POLIPEPTIDE FACTORS VII (FVII)
ECSP12011908A (en) OCTAHIDROPIRROLO [3,4-c] PIRROLOS DISUSTITUIDOS AS
MX356958B (en) Glucagon-like-peptide-2 (glp-2) analogues.
BRPI0920914A8 (en) ALPHA-KETO PERACIDS AND METHODS FOR PRODUCING AND USING THEM.
SV2009003393A (en) FACTOR POLIPEPTIDES VII MODIFICATIONS AND USES OF THE SAME
CR20140512A (en) DEVICES AND METHODS FOR THE MANUFACTURE OF IMPLANT COMPONENT ADDITIVES
AR084057A1 (en) COMPOSITIONS FOR FABRIC CARE
WO2012106281A3 (en) Multimodal trail molecules and uses in cellular therapies
CR20110630A (en) CARBOXAMIDE COMPOUNDS AND ITS USE AS CALPAIN INHIBITORS
CR11866A (en) DERIVATIVES OF PIRIDINO-PIRIDINONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
UY35703A (en) ANTIBODIES AGAINST THE INHIBITOR-1 OF THE PLASMINOGEN ACTIVATOR (PAI-1) AND USES OF THE SAME
GT200900309A (en) DERIVATIVES OF 7-ALQUINIL-1,8-NAFTIRIDONAS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
DOP2010000251A (en) EFFECTIVE PARAMYXOVIRUS AS ANTITUMORAL
UY32445A (en) COMPOSITION AND PROCEDURE TO USE AMINOPIRIDINS
ATE528013T1 (en) VACCINE COMPOSITIONS
PA8796001A1 (en) HISTAMINE H4-FURO-PYRIMIDINE MODULATORS OF THE H4 HISTAMINE RECEIVER
MX2012001409A (en) Modified agrin-fragment capable of restoring muscle strength for use as a medicament.
BR112014016803A2 (en) macrocyclic amides as protease inhibitors
CR11457A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HIALURONIC ACID AND USES OF THE SAME
UY29361A1 (en) PIRROLES AND IMIDAZOLS REPLACED, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE
ECSP13012613A (en) METHOD FOR PRODUCING AND USING A SOUND CARBOXIMETILCELLULOSE AND GOSIPOL COPOLYMER
MX349583B (en) Azeotropic compositions of 1,1,3,3-tetrachloro-1-fluoropropane and hydrogen fluoride.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)